See also:  The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus  Stocks In Focus Eyepoint In-Licenses Eye Disorder Drug From Equinox Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) announced the signing of an exclusive license agreement with Equinox Science for developing vorolanib, a tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.Brian Mueller, SVP, finance and chief accounting officer, has assumed the role of acting CFO, with the  company  initiating an internal and external search for a permanent replacement.